Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2023 - 01 - 09 tags : Pharma save search
Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Published: 2023-01-09 (Crawled : 23:00) - biospace.com/
OCUP | News | $1.53 2.2K
|
Health Technology
|
| O: 1.89%
H: 5.26%
C: 5.26%
nyxol pharma trial presbyopia
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-09 (Crawled : 15:00) - globenewswire.com
JNJ | News | $147.46 -0.72% 820K
|
Health Technology
|
| O: -0.53%
H: 0.26%
C: -2.07%
RPRX | $27.765 -0.77% 190K
|
Health Technology
|
| O: 0.53%
H: 3.12%
C: 2.38%
pharma royalty conference update
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
Published: 2023-01-09 (Crawled : 14:20) - biospace.com/
INZY | $4.18 -5.0% 39K
|
Health Technology
|
| O: 1.61%
H: 4.5%
C: -11.11%
pharma
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
Published: 2023-01-09 (Crawled : 14:20) - prnewswire.com
JNJ | News | $147.46 -0.72% 820K
|
Health Technology
|
| O: -0.53%
H: 0.26%
C: -2.07%
RPRX | $27.765 -0.77% 190K
|
Health Technology
|
| O: 0.53%
H: 3.12%
C: 2.38%
IONS | $42.195 -0.6% 99K
|
Health Technology
|
| O: -0.17%
H: 0.84%
C: -7.91%
pharma royalty commercial genetic agreement
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
Published: 2023-01-09 (Crawled : 14:20) - globenewswire.com
JNJ | News | $147.46 -0.72% 820K
|
Health Technology
|
| O: -0.53%
H: 0.26%
C: -2.07%
RPRX | $27.765 -0.77% 190K
|
Health Technology
|
| O: 0.53%
H: 3.12%
C: 2.38%
IONS | $42.195 -0.6% 99K
|
Health Technology
|
| O: -0.17%
H: 0.84%
C: -7.91%
pharma royalty commercial genetic agreement
FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
Published: 2023-01-09 (Crawled : 14:00) - biospace.com/
HUGE | News | $0.461 0.46% 580K
|
Process Industries
|
| O: -0.13%
H: 9.9%
C: 2.98%
pharma drug australia
2022 Corporate Reputation of Pharma Companies Report: Patient Perspective of 520 Cancer Patient Groups During 2021
Published: 2023-01-09 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: 1.38%
H: 0.28%
C: 0.28%
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: 0.0%
pharma companies cancer
Gainers vs Losers
| 46% | 54% |
Top 10 Gainers
SGBX | $0.26 80.43% 54M
|
Producer Manufacturing
LICN | $1.0 78.57% 3.3M
|
CSSE 4 | $0.2656 74.39% 9.7M
|
Consumer Services
BRFH 4 | $1.89 71.82% 32M
|
Manufacturing
ACON | $0.49 70.14% 24M
|
n/a
BOF | $1.95 66.67% 920K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.22 61.0% 720K
|
Technology Services
PCSA | $2.28 40.74% 37M
|
Producer Manufacturing
EVA | $0.626 39.14% 2.3M
|
Process Industries
Your saved searches
Save your searches and get alerts when important news are released.